EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Mechanistic Insights Into Ganoderma Lucidum for Diabetes Treatment via Network Pharmacology and Validation

Shengxiang Guo iD, Lan Yang, Jiali Zhou, Wu Luo, Beibei Nie, Xiaohong Zhong, Dongbo Liu, Xincong Kang

Diabetes, Metabolic Syndrome and Obesity · 2025-04 · Volume 18 · 1263-1284

DOI: 10.2147/dmso.s500955 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Metabolic Syndrome and Obesity, 2025-04. Verfasst von Shengxiang Guo und 7 weiteren Autor:innen. Beteiligte Einrichtung: College of Horticulture, Hunan Agricultural University, Changsha, 410128, People's Republic of China. Die Arbeit wurde bisher 5-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

There is an urgent need to develop antidiabetic medications with minimal side effects and low toxicity. Ganoderma lucidum, a food-medicine homologous in China, has been used to treat diabetes. This study was aimed to explore the active ingredients and mechanism of G. lucidum in the treatment of diabetes. Materials and Methods: Relevant compounds and targets of Ganoderma were collected from the TCMSP database, BATMAN-TCM database, relevant literature and PubChem. A diabetes-related target database was constructed using TTD, BATMAN-TCM, and Uniprot. A PPI network and H-C-T-P network were constructed to analyze interactions among these targets. GO and KEGG enrichment analyses were performed using WebGestalt. Molecular docking of the core compounds and key targets was carried out using AutoDock Vina. The predicted key targets were verified via qRT-PCR in PA-induced HepG2 cells, using GLAE (ethanol extract of Ganoderma lucidum) as the treatment.

Results

A total of 58 compounds were screened out in G. lucidum, of which 17 had predicted targets. G. lucidum was involved in metabolic processes, such as lipid binding, insulin secretion, and other pathways. Molecular docking results showed that the core component β-sitosterol had strong binding activity with key targets CASP3, PRKACA, and PGR. Based on the results of network pharmacology, the top 10 targets related to glucose and lipid metabolism were selected for validation. The results indicated that in a high-fat environment, glucose and lipid metabolism in HepG2 cells was improved, with decreased mRNA expression of CASP3, PRKACA, CYP19A1, NR3C1, JUN, and increased expression of PGR and RXRA.

Conclusion

Glucose and lipid metabolism are important for the anti-diabetic activity of G. lucidum. A strong interaction of β-sitosterol with CASP3, PRKACA, and PGR, which may be related to cell apoptosis, gluconeogenesis and insulin secretion, etc. This study lays the foundational groundwork for future drug development and therapeutic optimization.

Schlagwörter

Stichwörter der Autor:innen

Ganoderma lucidumcelldiabetesinsulin resistantmolecular dockingnetwork pharmacology

Autor:innen und Institutionen

  • College of Horticulture, Hunan Agricultural University, Changsha, 410128, People's Republic of China.
  • State Key Laboratory of Subhealth Intervention Technology, Changsha, 410128, People's Republic of China.
  • Hunan Provincial Engineering Research Center of Medical Nutrition Intervention Technology for Metabolic Diseases, Hunan Agricultural University, Changsha, 410128, People's Republic of China.
  • School of Pharmacy, North Sichuan Medical College, Nanchong, 637000, People's Republic of China.
  • National Research Center of Engineering Technology for Utilization of Botanical Functional Ingredients, Hunan Agricultural University, Changsha, 410128, People's Republic of China.

ORCID-Profile: Shengxiang Guo

Zitieren

APA

Guo, S., Yang, L., Zhou, J., Luo, W., Nie, B., Zhong, X., Liu, D., & Kang, X. (2025). Mechanistic Insights Into Ganoderma Lucidum for Diabetes Treatment via Network Pharmacology and Validation. Diabetes, Metabolic Syndrome and Obesity, Volume 18, 1263-1284. https://doi.org/10.2147/dmso.s500955

Vancouver

Guo S, Yang L, Zhou J, Luo W, Nie B, Zhong X, et al. Mechanistic Insights Into Ganoderma Lucidum for Diabetes Treatment via Network Pharmacology and Validation. Diabetes, Metabolic Syndrome and Obesity. 2025;Volume 18:1263-1284. doi:10.2147/dmso.s500955

BibTeX
@article{Guo2025,
  author = {Guo, Shengxiang and Yang, Lan and Zhou, Jiali and Luo, Wu and Nie, Beibei and Zhong, Xiaohong and Liu, Dongbo and Kang, Xincong},
  title = {Mechanistic Insights Into Ganoderma Lucidum for Diabetes Treatment via Network Pharmacology and Validation},
  journal = {Diabetes, Metabolic Syndrome and Obesity},
  year = {2025},
  volume = {Volume 18},
  pages = {1263--1284},
  doi = {10.2147/dmso.s500955}
}
Kostenlos starten →